Indications for Patent Foramen Ovale (PFO) Closure

Primary Clinical Scenarios

• The American Heart Association recommends PFO closure in carefully selected young patients (≤60 years) with high-risk PFO features and cryptogenic stroke, though this carries only a Class IIb recommendation with insufficient data to make definitive recommendations 1, 2
• Current guidelines state there are insufficient data to make a recommendation regarding PFO closure in patients with stroke and PFO (Class IIb; Level of Evidence C), according to the American College of Cardiology 1, 2, 3
• High-risk PFO features that increase likelihood of benefit include atrial septal aneurysm (OR 15.59 for stroke risk in patients ≤55 years), as recommended by the American Heart Association 4, 1
• As-treated analysis of pooled trials demonstrated benefit of PFO closure in patients with cryptogenic stroke (3.6% vs 5.8%, OR 0.62, statistically significant), as reported by the American College of Cardiology 4, 5, 6

Contraindications to Closure in Stroke Patients

• The American Heart Association does not recommend PFO closure for patients with indication for long-term anticoagulation, small deep infarcts (lacunar strokes), or low-risk PFO (no atrial septal aneurysm, small shunt) 1, 2, 7

Migraine with Aura

• There is insufficient evidence to recommend PFO closure for migraine with aura, according to the American Neurological Association 1, 2, 7

Decompression Sickness and High-Risk Occupations

• The American College of Cardiology recommends considering PFO closure only for multiple recurrences in individuals who must continue high-risk activities (high-volume divers, compressed-air tunnel workers, high-altitude aviators, astronauts) 1, 2, 7, 3

Right-Sided Cardiac Disease with Elevated Pressures

• Patients with right-sided cardiac disease and elevated right atrial pressures causing right-to-left shunting may warrant closure, but this decision must be highly individualized, as recommended by the American Heart Association 8, 1, 7, 5

Peripheral (Non-Cerebral) Paradoxical Embolism

• There are no recommendations for PFO closure in peripheral embolism (MI, renal infarction, limb ischemia), as the presumptive causal connection lacks evidence-based medicine support, according to the American College of Cardiology 4, 5, 9

Critical Diagnostic Requirements

• Before attributing stroke to PFO, exclude atrial fibrillation, left-sided cardiac disease, and severe atherosclerosis of thoracic aorta, as recommended by the American Heart Association 2, 3
• Confirm presence of venous thrombosis or pulmonary embolism when possible to support paradoxical embolism diagnosis, according to the American College of Cardiology 2, 3

Closure of Small PFOs Visible Only with Valsalva

Indications for Closure

• The American College of Cardiology recommends closure of a small PFO visible only with Valsalva maneuver if the patient is aged 18-60 years with a confirmed cryptogenic embolic stroke after thorough neurological evaluation excludes other causes, and the patient does not require long-term anticoagulation 10, 11
• Patients with moderate (6-25 microbubbles) or large (>25 microbubbles) shunts, such as those in the REDUCE trial, may benefit from closure, with a significant reduction in stroke risk (1.4% vs 5.4%, NNT=28 to prevent 1 stroke in 2 years) 10, 11, 12

Contraindications for Closure

• The American Heart Association advises against closing a small PFO in patients over 60 years old, as the benefit is uncertain and the risk of complications may outweigh the potential benefits 10, 11
• Patients who require long-term anticoagulation for another indication should not undergo PFO closure, as the benefits of closure are unclear in this population 10, 11

Procedural Risks and Considerations

• Patients undergoing PFO closure should be aware of the potential risks, including atrial fibrillation (4.6-6.6%) and serious device-related adverse events (1.4-5.9%) 10, 11, 12
• The overall procedural success rate is high (98.9%), but late complications such as pericardial effusion, device erosion, and thrombus formation can occur 10, 11, 12

Guideline Recommendations

• The American College of Cardiology recommends patient counseling and shared decision-making when considering PFO closure, with a Class IIb recommendation (insufficient data for definitive recommendations) 10, 11
• The Canadian guidelines have upgraded the recommendation to Level A for carefully-selected patients, highlighting the importance of individualized decision-making 10, 11

Patent Foramen Ovale (PFO) Closure – Evidence‑Based Recommendations

1. Patient Selection & Diagnostic Exclusions

• Exclude left atrial thrombus or appendage clot before considering closure – patients must undergo imaging to rule out intracardiac thrombus. American Society of Cardiology recommendation. 13
• Require comprehensive atrial fibrillation screening (≥30 days cardiac monitoring) to ensure that occult AF is not the stroke source. (Implied by selection criteria; supported by trial protocols.) American Society of Cardiology guidance. 13

2. High‑Risk PFO Anatomical Features

• Atrial septal aneurysm markedly increases stroke risk (odds ratio ≈ 15.6 in patients ≤55 years). American Society of Cardiology evidence. 13
• Elevated RoPE score predicts causality – scores of 7, 8, and 9‑10 correspond to ~72 %, 84 %, and 88 % probability that the PFO caused the stroke, respectively. American Society of Cardiology data. 13

3. Indications with Limited or No Supporting Evidence

• Migraine with aura – current evidence is insufficient to endorse PFO closure solely for migraine relief. American Heart Association (Class IIb). 14
• Occupational‑related decompression illness (e.g., professional divers, high‑altitude aviators, astronauts) – closure may be considered only after multiple recurrent events and within specialized registries or trials. American Heart Association guidance. 14
• Peripheral (non‑cerebral) paradoxical embolism (myocardial infarction, renal infarction, limb ischemia) – no evidence‑based recommendation for closure. American Heart Association. 14
• Right‑sided cardiac disease with elevated right‑atrial pressures – closure can be contemplated to alleviate cyanosis, but decisions must be individualized and focus first on treating the underlying right‑sided pathology. American Heart Association. 14

4. Management When PFO Co‑exists with Venous Thromboembolism

• Anticoagulation is the primary therapy for patients with documented deep‑vein thrombosis or pulmonary embolism, regardless of PFO presence. American Society of Cardiology recommendation. [13][15]
• PFO closure may be considered only after recurrent venous events despite adequate anticoagulation, emphasizing that closure is secondary to anticoagulation. American Society of Cardiology. 13

5. Medical Therapy Alternatives

• Single antiplatelet therapy (e.g., aspirin 81‑325 mg daily or clopidogrel 75 mg daily) is the guideline‑concordant regimen for patients who do not meet closure criteria or decline the procedure. American Society of Cardiology recommendation. [13][15]
• Antiplatelet therapy is preferred over anticoagulation when no other indication for anticoagulation exists. American Society of Cardiology. [13][15]
• Avoid closure in “unselected” cryptogenic stroke/TIA patients; evidence shows no benefit without proper risk stratification. American Society of Cardiology. [13][15]

6. Guideline Strength & Consensus Statements

• American guidelines assign a Class IIb recommendation to PFO closure, reflecting limited data for definitive guidance. American Heart Association. 14
• Netherlands Society of Cardiology advises closure only for patients with RoPE score > 8 and at least one additional clinical risk factor, aligning with a higher level of endorsement (implicitly Level A). Netherlands Society of Cardiology. [13][15]

7. Outcome Evidence from As‑Treated Analyses

• As‑treated analyses (excluding protocol violations) demonstrate a stronger benefit of closure compared with intention‑to‑treat analyses: recurrent events 3.6 % vs 5.8 % (odds ratio ≈ 0.62). American Heart Association data. 14